Virus-Like Nanotherapeutic for Spatiotemporally Enhancing Antigen Presentation and Cross-Presentation toward Potential Personalized Immunotherapy.


Journal

Advanced healthcare materials
ISSN: 2192-2659
Titre abrégé: Adv Healthc Mater
Pays: Germany
ID NLM: 101581613

Informations de publication

Date de publication:
10 2023
Historique:
revised: 13 07 2023
received: 22 03 2023
medline: 23 10 2023
pubmed: 2 8 2023
entrez: 2 8 2023
Statut: ppublish

Résumé

One of the major causes of immunotherapy resistance is the loss of major histocompatibility complex class I (MHC-I) molecules in tumor cells or the downregulation of the class I antigen presentation pathway. In this study, a novel virus-like nanotherapeutic (siRNA@HCM) is developed via encapsulating nanosized siRNA nanoparticles in a hybrid membrane comprising a personalized tumor cell membrane and a universal 293T membrane expressing the mutant vesicular stomatitis virus glycoprotein (mVSV-G). Upon intravenous administration, siRNA@HCM accumulates at the tumor site and provides two potent driving forces for antitumor immunity. First, mVSV-G induces the fusion of siRNA@HCM with tumor cell membranes and directly injects siRNAs into the cytoplasm, significantly improving tumor intrinsic MHC-I antigen presentation. Moreover, mVSV-G can promote the maturation of dendritic cells, thereby achieving highly efficient antigen cross-presentation. The results demonstrate that spatiotemporally enhancing tumor intrinsic antigen presentation and cross-presentation via siRNA@HCM can achieve satisfactory antitumor efficacy and excellent biocompatibility. Immune infiltration analysis shows that siRNA@HCM treatment turns cold tumors into hot tumors. In addition, it significantly promotes the therapeutic effect of programmed death-1 inhibitor. In summary, virus-like nanotherapeutics present a promising approach to enhance the antitumor immune response, with distinct advantages for potential personalized therapy and clinical applications.

Identifiants

pubmed: 37531246
doi: 10.1002/adhm.202300921
doi:

Substances chimiques

Histocompatibility Antigens Class I 0
Antigens, Neoplasm 0
RNA, Small Interfering 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2300921

Informations de copyright

© 2023 Wiley-VCH GmbH.

Références

a) J. R. Brahmer, C. G. Drake, I. Wollner, J. D. Powderly, J. Picus, W. H. Sharfman, E. Stankevich, A. Pons, T. M. Salay, T. L. McMiller, M. M. Gilson, C. Wang, M. Selby, J. M. Taube, R. Anders, L. Chen, A. J. Korman, D. M. Pardoll, I. Lowy, S. L. Topalian, J. Clin. Oncol. 2010, 28, 3167;
b) L. Gandhi, D. Rodriguez-Abreu, S. Gadgeel, E. Esteban, E. Felip, F. De Angelis, M. Domine, P. Clingan, M. J. Hochmair, S. F. Powell, S. Y. Cheng, H. G. Bischoff, N. Peled, F. Grossi, R. R. Jennens, M. Reck, R. Hui, E. B. Garon, M. Boyer, B. Rubio-Viqueira, S. Novello, T. Kurata, J. E. Gray, J. Vida, Z. Wei, J. Yang, H. Raftopoulos, M. C. Pietanza, M. C. Garassino, K.-189 Investigators, N. Engl. J. Med. 2018, 378, 2078;
c) M. Reck, D. Rodriguez-Abreu, A. G. Robinson, R. Hui, T. Csoszi, A. Fulop, M. Gottfried, N. Peled, A. Tafreshi, S. Cuffe, M. O'Brien, S. Rao, K. Hotta, M. A. Leiby, G. M. Lubiniecki, Y. Shentu, R. Rangwala, J. R. Brahmer, K.-024 Investigators, N. Engl. J. Med. 2016, 375, 1823.
a) P. Sharma, J. P. Allison, Science 2015, 348, 56;
b) D. S. Shin, A. Ribas, Curr. Opin. Immunol. 2015, 33, 23;
c) Y. Geng, Q. Zhang, S. Feng, C. Li, L. Wang, X. Zhao, Z. Yang, Z. Li, H. Luo, R. Liu, B. Lu, X. Wang, Cancer Med. 2021, 10, 1222;
d) R. L. Siegel, K. D. Miller, A. Jemal, Ca-Cancer J. Clin. 2017, 67, 7;
e) M. F. Sanmamed, L. Chen, Cell 2018, 175, 313.
a) X. Zhao, S. Subramanian, Cancer Res. 2017, 77, 817;
b) J. Wang, R. Yuan, W. Song, J. Sun, D. Liu, Z. Li, J. Hematol. Oncol. 2017, 10, 34.
A. J. Schoenfeld, M. D. Hellmann, Cancer Cell 2020, 37, 443.
a) B. Seliger, T. Cabrera, F. Garrido, S. Ferrone, Semin. Cancer Biol. 2002, 12, 3;
b) F. Garrido, N. Aptsiauri, E. M. Doorduijn, A. M. Garcia Lora, T. van Hall, Curr. Opin. Immunol. 2016, 39, 44.
a) F. Garrido, I. Romero, N. Aptsiauri, A. M. Garcia-Lora, Int. J. Cancer 2016, 138, 271;
b) K. Kukita, Y. Tamura, T. Tanaka, T. Kajiwara, G. Kutomi, K. Saito, K. Okuya, A. Takaya, T. Kanaseki, T. Tsukahara, Y. Hirohashi, T. Torigoe, T. Furuhata, K. Hirata, N. Sato, J. Immunol. 2015, 194, 4988;
c) B. K. Sadasivan, A. Cariappa, G. L. Waneck, P. Cresswell, Cold Spring Harb Symp Quant Biol 1995, 60, 267;
d) M. L. Burr, D. J. van den Boomen, H. Bye, R. Antrobus, E. J. Wiertz, P. J. Lehner, Proc. Natl. Acad. Sci. USA 2013, 110, 14290;
e) D. J. van den Boomen, R. T. Timms, G. L. Grice, H. R. Stagg, K. Skodt, G. Dougan, J. A. Nathan, P. J. Lehner, Proc. Natl. Acad. Sci. USA 2014, 111, 11425;
f) E. J. Wiertz, D. Tortorella, M. Bogyo, J. Yu, W. Mothes, T. R. Jones, T. A. Rapoport, H. L. Ploegh, Nature 1996, 384, 432.
M. L. Burr, C. E. Sparbier, K. L. Chan, Y.-C. Chan, A. Kersbergen, E. Y. N. Lam, E. Azidis-Yates, D. Vassiliadis, C. C. Bell, O. Gilan, S. Jackson, L. Tan, S. Q. Wong, S. Hollizeck, E. M. Michalak, H. V. Siddle, M. T. McCabe, R. K. Prinjha, G. R. Guerra, B. J. Solomon, S. Sandhu, S.-J. Dawson, P. A. Beavis, R. W. Tothill, C. Cullinane, P. J. Lehner, K. D. Sutherland, M. A. Dawson, Cancer Cell 2019, 36, 385.
a) D. Pasini, L. Di Croce, Curr. Opin. Genet. Dev. 2016, 36, 50;
b) J. A. Simon, C. A. Lange, Mutat Res 2008, 647, 21.
W. Peng, W. Tang, J. D. Li, R. Q. He, J. Y. Luo, Z. X. Chen, J. H. Zeng, X. H. Hu, J. C. Zhong, Y. Li, F. C. Ma, T. Y. Xie, S. N. Huang, L. Y. Ge, PeerJ 2022, 10, 13708.
S. L. Nutt, C. Keenan, M. Chopin, R. S. Allan, Biol. Chem. 2020, 401, 933.
T. Ito, Y. V. Teo, S. A. Evans, N. Neretti, J. M. Sedivy, Cell Rep. 2018, 22, 3480.
a) T. B. Miranda, C. C. Cortez, C. B. Yoo, G. Liang, M. Abe, T. K. Kelly, V. E. Marquez, P. A. Jones, Mol. Cancer Ther. 2009, 8, 1579;
b) R. Fioravanti, G. Stazi, C. Zwergel, S. Valente, A. Mai, Chem. Rec. 2018, 18, 1818;
c) T. A. Yap, J. N. Winter, L. Giulino-Roth, J. Longley, J. Lopez, J. M. Michot, J. P. Leonard, V. Ribrag, M. T. McCabe, C. L. Creasy, M. Stern, T. Pene Dumitrescu, X. Wang, S. Frey, J. Carver, T. Horner, C. Oh, A. Khaled, A. Dhar, P. W. M. Johnson, Clin. Cancer Res. 2019, 25, 7331;
d) S. Huang, Z. Wang, J. Zhou, J. Huang, L. Zhou, J. Luo, Y. Y. Wan, H. Long, B. Zhu, Cancer Res. 2019, 79, 2009.
X. Liu, X. Bao, M. Hu, H. Chang, M. Jiao, J. Cheng, L. Xie, Q. Huang, F. Li, C. Y. Li, Nature 2020, 588, 693.
S. J. Lee, M. J. Kim, I. C. Kwon, T. M. Roberts, Adv. Drug Delivery Rev. 2016, 104, 2.
a) Y. Bu, Q. Hu, R. Ke, Y. Sui, X. Xie, S. Wang, Chem. Commun. 2018, 54, 13427;
b) W. Xie, W. W. Deng, M. Zan, L. Rao, G. T. Yu, D. M. Zhu, W. T. Wu, B. Chen, L. W. Ji, L. Chen, K. Liu, S. S. Guo, H. M. Huang, W. F. Zhang, X. Zhao, Y. Yuan, W. Dong, Z. J. Sun, W. Liu, ACS Nano 2019, 13, 2849;
c) C. H. Xu, P. J. Ye, Y. C. Zhou, D. X. He, H. Wei, C. Y. Yu, Acta Biomater. 2020, 105, 1;
d) Y. Zhai, J. Su, W. Ran, P. Zhang, Q. Yin, Z. Zhang, H. Yu, Y. Li, Theranostics 2017, 7, 2575;
e) R. Zhang, S. Wu, Q. Ding, Q. Fan, Y. Dai, S. Guo, Y. Ye, C. Li, M. Zhou, Drug Delivery 2021, 28, 1109;
f) L. Zhang, R. Li, H. Chen, J. Wei, H. Qian, S. Su, J. Shao, L. Wang, X. Qian, B. Liu, Int. J. Nanomed. 2017, 12, 2129.
J. Cronin, X. Y. Zhang, J. Reiser, Curr. Gene Ther. 2005, 5, 387.
P. Fonte, S. Reis, B. Sarmento, J. Controlled Release 2016, 225, 75.
H. C. Verdera, K. Kuranda, F. Mingozzi, Mol. Ther. 2020, 28, 723.
P. Cukier, F. C. Santini, M. Scaranti, A. O. Hoff, Endocr Relat Cancer 2017, 24, T331.
a) N. K. Altorki, G. J. Markowitz, D. Gao, J. L. Port, A. Saxena, B. Stiles, T. McGraw, V. Mittal, Nat. Rev. Cancer 2019, 19, 9;
b) S. Spranger, T. F. Gajewski, Oncoimmunology 2016, 5, 1086862;
c) J. M. Pitt, M. Vetizou, R. Daillere, M. P. Roberti, T. Yamazaki, B. Routy, P. Lepage, I. G. Boneca, M. Chamaillard, G. Kroemer, L. Zitvogel, Immunity 2016, 44, 1255;
d) D. P. Mysona, L. Tran, S. Bai, B. Dos Santos, S. Ghamande, J. Chan, J. X. She, Am. J. Cancer Res. 2021, 11, 181;
e) A. J. Rucker, F. K. Chan, Trends Biochem. Sci. 2022, 47, 342.
C. Bernsmeier, S. van der Merwe, A. Perianin, J Hepatol 2020, 73, 186.
M. L. M. Jongsma, G. Guarda, R. M. Spaapen, Mol. Immunol. 2019, 113, 16.
a) A. Schlitzer, F. Ginhoux, Curr. Opin. Immunol. 2014, 26, 90;
b) C. Liu, X. Liu, X. Xiang, X. Pang, S. Chen, Y. Zhang, E. Ren, L. Zhang, X. Liu, P. Lv, X. Wang, W. Luo, N. Xia, X. Chen, G. Liu, Nat. Nanotechnol. 2022, 17, 531.
a) H. Salmon, J. Idoyaga, A. Rahman, M. Leboeuf, R. Remark, S. Jordan, M. Casanova-Acebes, M. Khudoynazarova, J. Agudo, N. Tung, S. Chakarov, C. Rivera, B. Hogstad, M. Bosenberg, D. Hashimoto, S. Gnjatic, N. Bhardwaj, A. K. Palucka, B. D. Brown, J. Brody, F. Ginhoux, M. Merad, Immunity 2016, 44, 924;
b) E. W. Roberts, M. L. Broz, M. Binnewies, M. B. Headley, A. E. Nelson, D. M. Wolf, T. Kaisho, D. Bogunovic, N. Bhardwaj, M. F. Krummel, Cancer Cell 2016, 30, 324.
J. P. Boettcher, C. Reise Sousa, Trends Cancer 2018, 4, 784.
P. Bonaventura, T. Shekarian, V. Alcazer, J. Valladeau-Guilemond, S. Valsesia-Wittmann, S. Amigorena, C. Caux, S. Depil, Front Immunol 2019, 10, 168.
G. B. Kim, G. H. Nam, Y. Hong, J. Woo, Y. Cho, I. C. KWon, Y. Yang, I. S. Kim, Sci. Adv. 2020, 6, 27.
S. Iborra, H. M. Izquierdo, M. Martinez-Lopez, N. Blanco-Menendez, C. Reis e Sousa, D. Sancho, J. Clin. Invest. 2012, 122, 1628.
D. Matheoud, L. Perie, G. Hoeffel, L. Vimeux, I. Parent, C. Maranon, P. Bourdoncle, L. Renia, A. Prevost-Blondel, B. Lucas, V. Feuillet, A. Hosmalin, Blood 2010, 115, 4412.
N. Wathelet, M. Moser, Oncoimmunology 2013, 2, 23973.
A. Sucker, F. Zhao, N. Pieper, C. Heeke, R. Maltaner, N. Stadtler, B. Real, N. Bielefeld, S. Howe, B. Weide, R. Gutzmer, J. Utikal, C. Loquai, H. Gogas, L. Klein-Hitpass, M. Zeschnigk, A. M. Westendorf, M. Trilling, S. Horn, B. Schilling, D. Schadendorf, K. G. Griewank, A. Paschen, Nat. Commun. 2017, 8, 15440.
C. S. Garris, S. P. Arlauckas, R. H. Kohler, M. P. Trefny, S. Garren, C. Piot, C. Engblom, C. Pfirschke, M. Siwicki, J. Gungabeesoon, G. J. Freeman, S. E. Warren, S. Ong, E. Browning, C. G. Twitty, R. H. Pierce, M. H. Le, A. P. Algazi, A. I. Daud, S. I. Pai, A. Zippelius, R. Weissleder, M. J. Pittet, Immunity 2018, 49, 1148.

Auteurs

Xiaodi Li (X)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Pengfei Yuan (P)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Haiyuan Yang (H)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Xiaoqing Zong (X)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Caiqi Yang (C)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Xinjie Chen (X)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Yuchao Li (Y)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Xiaodie Yan (X)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Yaoqi Wen (Y)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Tianci Zhu (T)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Qian Zhang (Q)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Wei Xue (W)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Jian Dai (J)

Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Engineering Technology Research Center of Drug Carrier of Guangdong, Department of Biomedical Engineering, Jinan University, Guangzhou, 510632, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH